NovaBridge Biosciences to Participate in September Investor Conferences
Rhea-AI Summary
NovaBridge Biosciences (Nasdaq: NBP) announced that CEO Srishti Gupta will present at two investor conferences in September 2026. She will join fireside chats and one-on-one meetings at the Cantor 2026 Global Healthcare Conference on September 10, 2026 at 1:00 PM ET and the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 at 9:30 AM ET. Webcasts of both sessions will be available on NovaBridge’s News & Events webpage for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – NBP
In the Aug 27 session, NBP gained 1.07%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 20 | First-half earnings | Negative | -3.5% | Net loss widened despite pipeline progress and reported liquidity supporting milestones. |
| Aug 13 | Earnings date announcement | Neutral | +3.2% | Scheduled the first-half results webcast and corporate update for August 20, 2026. |
| Jul 24 | Annual meeting notice | Neutral | +0.6% | Set the shareholder meeting, voting record date, and proxy deadlines for September. |
| Jun 29 | CEO appointment | Positive | +20.7% | Named Srishti Gupta CEO and board member effective July 1, 2026. |
| Jun 16 | FDA Fast Track | Positive | +2.7% | Received FDA Fast Track Designation for givastomig in first-line gastric cancer. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Four of the five recent news events were followed by gains, while the latest earnings report was followed by a decline.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., Aug. 27, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced that the Company’s leadership will participate in the following investor conferences in September 2026:
Conference details:
Cantor 2026 Global Healthcare Conference
Format: Fireside Chat and one-on-one meetings
Presenter: Srishti Gupta, MD, MPP, Chief Executive Officer, NovaBridge Biosciences
Date: Thursday, September 10, 2026
Time: 1:00 PM ET
Webcast Link: Here
H.C. Wainwright 28th Annual Global Investment Conference
Format: Fireside Chat and one-on-one meetings
Presenter: Srishti Gupta, MD, MPP, Chief Executive Officer, NovaBridge Biosciences
Date: Monday, September 14, 2026
Time: 9:30 AM ET
Webcast Link: Here
Webcasts of the Fireside chats will be accessible in the News & Events page of the NovaBridge website for 90 days.
About NovaBridge
NovaBridge Biosciences (Nasdaq: NBP) is a global biotechnology company advancing a portfolio of therapeutic programs in oncology and ophthalmology. The Company identifies differentiated therapeutic opportunities, generates value-defining clinical evidence, and applies the development, financing, and partnering strategy best suited to each program.
NovaBridge’s portfolio is led by givastomig and VIS-101. The Company's objective is to build a sustainable biotechnology company by repeatedly identifying differentiated innovation, advancing it efficiently, and bringing novel therapies to patients through the path best suited to each opportunity.
For more information, please visit www.novabridge.com and follow us on LinkedIn.
NovaBridge Investor & Media Contacts
NovaBridge Biosciences
+1-240-745-6330
IR@novabridge.com
Bill Begien, VP, Investor Relations
bill.begien@novabridge.com
Jessica Zhang, Director, Public Relations
jessica.zhang@novabridge.com
